Arrowhead Pharmaceuticals, Inc.
General ticker "ARWR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $8.7B (TTM average)
Arrowhead Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 50.5%.
Estimated limits based on current volatility of 2.4%: low 56.34$, high 59.15$
Factors to consider:
- Total employees count: 711 (+16.7%) as of 2025
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Intellectual property risks, Manufacturing issues, Liquidity and credit risks
- Current price 80.8% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-09-30 to 2027-09-30
- 2025-09-30 to 2026-09-30 estimated range: [17.66$, 36.75$]
- 2026-09-30 to 2027-09-30 estimated range: [14.26$, 30.92$]
Financial Metrics affecting the ARWR estimates:
- Positive: with PPE of -407.5 at the end of fiscal year the price was neutral
- Positive: 11.29 < Operating profit margin, % of 11.86
- Positive: 2.37 < Operating cash flow per share per price, % of 4.12
- Positive: 1.88 < Return on assets ratio (scaled to [-100,100]) of 2.13
- Positive: -4.49 < Investing cash flow per share per price, % of -2.97
- Negative: 25.20 < Shareholder equity ratio, % of 33.64 <= 34.41
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ARWR quotes
Long-term ARWR plot with estimates
Financial data
| YTD | 2023-09-30 | 2024-09-30 | 2025-09-30 |
|---|---|---|---|
| Operating Revenue | $240.74MM | $3.55MM | $829.45MM |
| Operating Expenses | $445.74MM | $604.63MM | $731.10MM |
| Operating Income | $-205.00MM | $-601.08MM | $98.35MM |
| Non-Operating Income | $-1.49MM | $-11.38MM | $-46.81MM |
| Interest Expense | $18.33MM | $32.35MM | $89.36MM |
| R&D Expense | $353.19MM | $505.87MM | $607.16MM |
| Income(Loss) | $-206.49MM | $-612.46MM | $51.53MM |
| Taxes | $2.78MM | $-2.77MM | $21.42MM |
| Net Income(Loss)* | $-205.28MM | $-599.49MM | $-1.63MM |
| Stockholders Equity | $271.34MM | $185.44MM | $466.05MM |
| Assets | $765.55MM | $1,139.80MM | $1,385.30MM |
| Operating Cash Flow | $-153.89MM | $-462.85MM | $179.55MM |
| Capital expenditure | $176.74MM | $141.47MM | $22.67MM |
| Investing Cash Flow | $-96.16MM | $-420.07MM | $-129.29MM |
| Financing Cash Flow | $253.05MM | $870.52MM | $74.01MM |
| Earnings Per Share** | $-1.92 | $-5.00 | $-0.01 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.